BI 113608 + ketoconazole

BI 113608 + ketoconazole refers to the investigational co-administration of BI 113608, a small-molecule drug under clinical development by Boehringer Ingelheim, with the strong CYP3A4 inhibitor ketoconazole. BI 113608 was being studied primarily for respiratory indications, notably chronic bronchitis associated with COPD. The purpose of the combination is to evaluate the pharmacokinetic interaction, as ketoconazole inhibits CYP3A4 and may alter BI 113608 plasma exposure. There is no evidence that this combination is marketed or used therapeutically outside of controlled pharmacokinetic or drug-drug interaction studies[1][2][4][6].